'Bribery at GSK pushed up drug prices' say Chinese authorities

Chinese authorities have accused a British GlaxoSmithKline (GSK) executive of ordering staff to bribe hospital officials to use its products.

The move helped generate billions of yuan in "illegal revenue", police said.

The UK man, Mark Reilly, and two other colleagues were also suspected of bribing government officials in Beijing and Shanghai, they said.

A representative of the Economic Crime Unit at the Public Security Bureau, who refused to be named, said GSK's behaviour "demonstrates a complete chain in bribery".

Celia Hatton reports.